Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced the distribution of a year-end letter from Chief Executive Officer, Benjamin Lightburn, which can be viewed on Filament’s website.

The letter highlights key milestones achieved by the Company including beginning the first ever FDA clinical trial of natural psychedelics at the University of California San Francisco, the closing of a $2.5 million dollar non-brokered financing led by Negev Capital and NAMMEX, and press coverage in The Wall Street Journal, Forbes, and the Toronto Star.

Leadership Announcements
Filament also announced that Greg Mills will step down from his position as Chair of the Company’s board of directors, effective December 31, 2022. Benjamin Lightburn will take over the role.

Mills, who will remain available to advise management, commented: “Having been part of Filament’s leadership team since its inception, I am proud of the Company’s ongoing progress and confident in its exceptional management team.”

Additionally, Dr. Konstantin Adamsky, Chief Operating Officer of Negev Capital and current independent member of Filament’s board of directors, will be joining the Company’s audit committee, compensation committee, and corporate governance and nominating committee. Maureen O’Connell and Chris Wagner, both independent directors, will continue to serve on the Company’s audit committee.


Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. We are paving the way with the first-ever natural psychedelic drug candidates.